IL315346A - CGAS agonistic quinoline compounds - Google Patents
CGAS agonistic quinoline compoundsInfo
- Publication number
- IL315346A IL315346A IL315346A IL31534624A IL315346A IL 315346 A IL315346 A IL 315346A IL 315346 A IL315346 A IL 315346A IL 31534624 A IL31534624 A IL 31534624A IL 315346 A IL315346 A IL 315346A
- Authority
- IL
- Israel
- Prior art keywords
- quinoline
- antagonist compounds
- cgas
- cgas antagonist
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263315968P | 2022-03-02 | 2022-03-02 | |
| US202363478467P | 2023-01-04 | 2023-01-04 | |
| PCT/US2023/063623 WO2023168367A1 (en) | 2022-03-02 | 2023-03-02 | QUINOLINE cGAS ANTAGONIST COMPOUNDS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL315346A true IL315346A (en) | 2024-11-01 |
Family
ID=85781707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315346A IL315346A (en) | 2022-03-02 | 2023-03-02 | CGAS agonistic quinoline compounds |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US12281078B2 (https=) |
| EP (1) | EP4486734A1 (https=) |
| JP (1) | JP2025507820A (https=) |
| KR (1) | KR20250004639A (https=) |
| CN (1) | CN119137112A (https=) |
| AU (1) | AU2023228915A1 (https=) |
| CA (1) | CA3253386A1 (https=) |
| IL (1) | IL315346A (https=) |
| MX (1) | MX2024010674A (https=) |
| TW (1) | TW202342021A (https=) |
| WO (1) | WO2023168367A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230062845A (ko) | 2020-09-03 | 2023-05-09 | 이뮨센서 테라퓨틱스, 인코포레이티드 | 퀴놀린 cgas 길항제 화합물 |
| IL315346A (en) | 2022-03-02 | 2024-11-01 | Immunesensor Therapeutics Inc | CGAS agonistic quinoline compounds |
| US20260092048A1 (en) | 2024-08-30 | 2026-04-02 | Immunesensor Therapeutics, Inc. | Solid forms and salts of a quinoline cgas antagonist compound |
| WO2026057087A1 (zh) * | 2024-09-14 | 2026-03-19 | 杭州英创医药科技有限公司 | 作为cGAS抑制剂的化合物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3542785A (en) * | 1967-05-15 | 1970-11-24 | Ciba Geigy Corp | 2-hydroxy-4-aryl-quinolines |
| US3668207A (en) * | 1970-01-22 | 1972-06-06 | Ciba Geigy Corp | 2-amino-4-aryl-quinolines |
| BR0312204A (pt) * | 2002-06-27 | 2005-04-26 | Schering Ag | Antagonista de receptor ccr5 de quinolina substituìda |
| CA2699697A1 (en) | 2007-09-27 | 2009-04-02 | F. Hoffmann-La Roche Ag | Quinoline derivatives as 5ht5a receptor antagonists |
| US20190127354A1 (en) * | 2015-12-14 | 2019-05-02 | Fundación Para La Investigación Médica Aplicada | 2,4,6,7-tetrasubstituted quinoline compounds as inhibitors of dna methyltransferases |
| CN109111426B (zh) | 2017-06-23 | 2021-12-14 | 中国科学院上海药物研究所 | 一类稠合双环杂芳基或芳基化合物，及其用途 |
| KR20240151869A (ko) | 2017-09-08 | 2024-10-18 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Enpp1 저해제 및 암의 치료용의 이의 용도 |
| WO2019241787A1 (en) | 2018-06-15 | 2019-12-19 | The Regents Of The University Of Colorado A Body Corporate | Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use |
| PL3829581T3 (pl) | 2018-07-27 | 2024-07-01 | Arcus Biosciences, Inc. | Antagoniści pirydonu a2r |
| EP3620164A1 (en) * | 2018-09-05 | 2020-03-11 | Genoscience Pharma SAS | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases |
| CA3125626A1 (en) | 2019-01-04 | 2020-07-09 | Bellbrook Labs, Llc | Inhibitors of cgas activity as therapeutic agents |
| CA3164995A1 (en) | 2019-12-20 | 2021-06-24 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| AU2021211437A1 (en) | 2020-01-20 | 2022-09-15 | Crescenta Biosciences | Novel cell metabolism modulating compounds and uses thereof |
| WO2022010948A1 (en) | 2020-07-06 | 2022-01-13 | Crescenta Biosciences | Novel cell metabolism modulating compounds and uses thereof for the treatment of viral diseases |
| KR20230062845A (ko) | 2020-09-03 | 2023-05-09 | 이뮨센서 테라퓨틱스, 인코포레이티드 | 퀴놀린 cgas 길항제 화합물 |
| IL315346A (en) | 2022-03-02 | 2024-11-01 | Immunesensor Therapeutics Inc | CGAS agonistic quinoline compounds |
-
2023
- 2023-03-02 IL IL315346A patent/IL315346A/en unknown
- 2023-03-02 EP EP23714185.8A patent/EP4486734A1/en active Pending
- 2023-03-02 US US18/177,732 patent/US12281078B2/en active Active
- 2023-03-02 AU AU2023228915A patent/AU2023228915A1/en active Pending
- 2023-03-02 TW TW112107684A patent/TW202342021A/zh unknown
- 2023-03-02 CN CN202380037098.5A patent/CN119137112A/zh active Pending
- 2023-03-02 CA CA3253386A patent/CA3253386A1/en active Pending
- 2023-03-02 KR KR1020247032755A patent/KR20250004639A/ko active Pending
- 2023-03-02 WO PCT/US2023/063623 patent/WO2023168367A1/en not_active Ceased
- 2023-03-02 JP JP2024551891A patent/JP2025507820A/ja active Pending
- 2023-07-17 US US18/353,718 patent/US12091387B2/en active Active
-
2024
- 2024-08-30 MX MX2024010674A patent/MX2024010674A/es unknown
-
2025
- 2025-02-27 US US19/066,046 patent/US20260042737A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4486734A1 (en) | 2025-01-08 |
| TW202342021A (zh) | 2023-11-01 |
| CA3253386A1 (en) | 2023-09-07 |
| MX2024010674A (es) | 2024-11-08 |
| WO2023168367A1 (en) | 2023-09-07 |
| CN119137112A (zh) | 2024-12-13 |
| JP2025507820A (ja) | 2025-03-21 |
| US20260042737A1 (en) | 2026-02-12 |
| US12091387B2 (en) | 2024-09-17 |
| US12281078B2 (en) | 2025-04-22 |
| US20240002346A1 (en) | 2024-01-04 |
| AU2023228915A1 (en) | 2024-09-19 |
| KR20250004639A (ko) | 2025-01-08 |
| US20230357158A1 (en) | 2023-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL315346A (en) | CGAS agonistic quinoline compounds | |
| IL300211B1 (en) | Antagonist compounds | |
| PT4320112T (pt) | Compostos de oxoisoindolina substituídos por piridinilo | |
| GB202200735D0 (en) | Compounds | |
| GB202216325D0 (en) | Compound | |
| EP4089082A4 (en) | QUINOLINE COMPOUNDS | |
| HK40122510A (en) | Quinoline cgas antagonist compounds | |
| GB202201151D0 (en) | Antagonist compounds | |
| GB202302314D0 (en) | Compound | |
| GB202217858D0 (en) | Compound | |
| GB202006823D0 (en) | Antagonist compounds | |
| AU2020290734B2 (en) | CGRP antagonist compounds | |
| GB202201996D0 (en) | Compounds | |
| GB202005877D0 (en) | H4 antagonist compounds | |
| GB202005858D0 (en) | H4 Antagonist compounds | |
| IL321606A (en) | EP2 antagonist compounds | |
| GB202000906D0 (en) | Antagonist | |
| GB202506745D0 (en) | SRSF1 antagonist | |
| GB202413855D0 (en) | Srsf1 antagonist | |
| HK40094661A (en) | H4 antagonist compounds | |
| EP4359399A4 (en) | EP2 antagonist compounds | |
| HK40084845A (en) | H4 antagonist compounds | |
| GB201904158D0 (en) | Antagonist compounds | |
| IL317958A (en) | CD73 compounds | |
| CA3276735A1 (en) | Ep2 antagonist compounds |